Virtual Clinical Trials Market Report 2026

The virtual clinical trials market size has grown rapidly in recent years. It will grow from $12.95 billion in 2025 to $14.36 billion in 2026 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to rising need for faster drug development, challenges in traditional clinical trial participation, increasing technology adoption in healthcare research, regulatory support for decentralized models, rising patient engagement initiatives.

The virtual clinical trials market size is expected to see rapid growth in the next few years. It will grow to $21.58 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to growing demand for remote healthcare solutions, expansion of precision medicine trials, increasing use of digital patient monitoring tools, rising investment in digital clinical infrastructure, continuous innovation in decentralized trial technologies. Major trends in the forecast period include growing adoption of remote clinical trial participation, increasing use of wearables and connected health devices, rising shift toward patient centric clinical research models, growing utilization of digital platforms for clinical monitoring, increasing focus on reducing site based clinical dependencies.

The rising number of clinical trials is expected to drive the growth of the virtual clinical trials market in the coming years. Clinical trials are research studies carried out on human participants to assess the safety, effectiveness, and potential benefits of new medical treatments, interventions, or drugs. The increase in clinical trials has created opportunities for the expansion and advancement of virtual clinical trials, which provide a more efficient, cost-effective, and patient-centric approach to conducting clinical research. For example, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, the number of pharmaceutical industry trials initiated in the UK increased for the second consecutive year, rising from 411 in 2022 to 426 in 2023. Therefore, the growing number of clinical trials is driving the expansion of the virtual clinical trials market during the forecast period.

Major companies operating in the virtual clinical trials market are focusing on developing advanced solutions, such as no-code digital trial platforms, to streamline complex clinical workflows. No-code digital solutions enable users to design, configure, and deploy clinical trial components without requiring deep technical expertise, reducing development time, improving accuracy, and enhancing operational efficiency. For instance, in August 2024, Medable Inc., a US-based clinical trial technology company, launched Medable Studio as part of its digital trial platform. This solution allows sponsors to build, translate, validate, and launch eCOA, eConsent, Televisit, and sensor-based workflows through an intuitive point-and-click interface, replacing traditional manual and service-heavy configuration processes. It provides real-time visibility into study content, scheduling, translations, and user flows, while enabling teams to customize protocol-specific designs without lengthy professional service cycles. Integrated with Medable’s broader digital trial ecosystem, the platform accelerates study start-up, improves operational control, and reduces trial timelines and costs.

In February 2024, PCM Trials, a home health care service based in the U.S., acquired EmVenio Research Inc. for an undisclosed amount. This acquisition is intended to enhance both PCM Trials' and EmVenio's capabilities in recruiting and retaining diverse populations for clinical research, which is essential for regulatory approval. The partnership gives PCM Trials access to EmVenio's site network that targets underserved communities, promoting patient-centric clinical trials and improving retention and diversity. EmVenio Research Inc. is a U.S.-based company dedicated to enabling virtual clinical trials through advanced technology and data analytics to create more efficient research processes.

Major companies operating in the virtual clinical trials market report are ICON plc, Parexel International Pvt. Ltd., IQVIA Holdings Inc., Covance Research Products Inc., Pharmaceutical Research Associates Inc., Medidata Solution Inc., Oracle Corporation, Clario Tech Ltd., Medable Inc., Science 37 Holdings Inc., THREAD Research, Clinical Ink Inc., Veeva Systems Inc., Clinerion Ltd., CRF Health Group Limited, Crio Inc., Deep Lens Inc., Florence Healthcare Inc., goBalto Inc., Medrio Inc., Mint Medical Ltd., Mytrus Inc., OpenClinica LLC, PatientWing, RealTime-CTMS LLC, Reify Health, Sanguine Biosciences Inc., TriNetX Inc., VirTrial LLC.

North America was the largest region in the virtual clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the virtual clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the virtual clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The virtual clinical trials market includes revenues earned by entities by providing services such as pilot studies and feasibility studies, prevention trials, screening trials, treatment trials, multi-arm multi-stage (mams) trials, cohort studies, case control studies, and cross sectional studies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.